PlumX Metrics
Embed PlumX Metrics

Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024

Morbidity and Mortality Weekly Report, ISSN: 1545-861X, Vol: 73, Issue: 32, Page: 696-702
2024
  • 19
    Citations
  • 0
    Usage
  • 18
    Captures
  • 5
    Mentions
  • 34
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    19
    • Citation Indexes
      15
    • Policy Citations
      4
      • Policy Citation
        4
  • Captures
    18
  • Mentions
    5
    • News Mentions
      5
      • News
        5
  • Social Media
    34
    • Shares, Likes & Comments
      34
      • Facebook
        34

Most Recent News

FDA says RSV vaccines must come with Guillain-Barré warning

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and Pfizer based on data that suggest there may be a link between the shots and the rare disorder. The agency said the benefits of receiving one of the vaccines still outweigh the risks. “FDA has determined that the overall body of evidence suggests increased risks of [Guillain

Article Description

Respiratory syncytial virus (RSV) is a major cause of respiratory illness and hospitalization in older adults during fall and winter in the United States. The 2023-2024 RSV season was the first during which RSV vaccination was recommended for U.S. adults aged ≥60 years, using shared clinical decision-making. On June 26, 2024, the Advisory Committee on Immunization Practices voted to update this recommendation as follows: a single dose of any Food and Drug Administration- approved RSV vaccine (Arexvy [GSK]; Abrysvo [Pfizer]; or mResvia [Moderna]) is now recommended for all adults aged ≥75 years and for adults aged 60-74 years who are at increased risk for severe RSV disease. Adults who have previously received RSV vaccine should not receive another dose. This report summarizes the evidence considered for these updated recommendations, including postlicensure data on vaccine effectiveness and safety, and provides clinical guidance for the use of RSV vaccines in adults aged ≥60 years. These updated recommendations are intended to maximize RSV vaccination coverage among persons most likely to benefit, by clarifying who is at highest risk and by reducing implementation barriers associated with the previous shared clinical decision-making recommendation. Continued postlicensure monitoring will guide future recommendations.

Bibliographic Details

Britton, Amadea; Roper, Lauren E; Kotton, Camille N; Hutton, David W; Fleming-Dutra, Katherine E; Godfrey, Monica; Ortega-Sanchez, Ismael R; Broder, Karen R; Talbot, H Keipp; Long, Sarah S; Havers, Fiona P; Melgar, Michael

Centers for Disease Control MMWR Office

Medicine; Social Sciences; Environmental Science; Health Professions

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know